Summary
We employed a test model, which we had developed for the investigation of platelet adhesiveness and aggregation in vivo. Our experiments demonstrated that somatostatin is not only able to dose-dependently inhibit the stickiness of i.v. injected Walker 256 carcinosarcoma cells to the vascular endothelium of the rat mesentery and the drastic, immediate reduction of platelet count in venous blood, but also to significantly reduce the rate of instantly occurring terminal tumor cell embolism of the lung. These actions may be explained as being mediated via an inhibition of platelet adhesion and aggregation to circulating cancer cells.
Because some oral antidiabetics showed a similar but weaker effect in our test system (Gastpar et al. 1982), it should be examined as to whether the in vivo inhibition of platelet adhesiveness and aggregation of the investigated compounds are mediated by a somatostatin release from the pancreas.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Efendić S, Enzmann F, Nylén A, Uvnas-Wallensten K, Luft R (1979) Effect of glucose/sulfonyl-urea interaction on release of insulin, glucagon and somatostatin from isolated perfused rat pancreas. Proc Natl Acad Sci USA 76:5901–5904
Efendić S, Enzmann F, Nylén A, Uvnas-Wallensten K, Luft R (1980) Sulfonylurea (Glibenclamide) enhances somatostatin and inhibits glucagon release induced by arginine. Acta Physiol Scand 108:231–233
Efendić S, Enzmann F, Gutniak M, Nylén A, Zoltobrocki M (1981) Insulin, glucagon and somatostatin in the perfused rat pancreas and the effects of HB 699 (4-(2-(5-chloro-2 metoxy-benzamido)-ethyl)-benzoic acid). Acta Endocrinol 98:573–579
Finney DJ (1952) Probit analysis, 2nd edn. Cambridge University Press, Cambridge
Gastpar H, Weissgerber PW, Enzmann F, Zoltobrocki M (1982) The inhibition of cancer cell stickiness, a model for investigation of platelet aggregation inhibitors in vivo. Effect of the sulfonylurea derivatives, glibenclamide, gliclacide and HB 180, as well as the carboxylic acid derivative, meglitinide. Res Exp Med (Berl) 180:75–84
Gutniak M, Zoltobrocki M, Efendić S (1983) Effects of the hypoglycemic agents, glibenclamide and 4-(2-(5-chloro-2 metoxy-benzamido)ethyl)-benzoic acid (HB 699), on the release of insulin, glucagon and growth hormone in healthy humans. Acta Endocrinol (in press)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gastpar, H., Zoltobrocki, M. & Weissgerber, P.W. The inhibition of cancer cell stickiness by somatostatin. Res. Exp. Med. 182, 1–6 (1983). https://doi.org/10.1007/BF01852280
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01852280